Prenatal And Newborn Genetic Testing Market Poised for 12.1 % Growth, Set to Hit $6.16 Billion by 2029

What market dynamics are playing a key role in accelerating the growth of the prenatal and newborn genetic testing market?
The anticipated expansion of the prenatal and newborn genetic testing markets is likely to be boosted by government strategies and assistance for prenatal evaluations and infant genetic screening. These government initiatives typically manifest in the form of specific programs, actions, rules, or projects implemented at national, regional, or local levels to tackle specific issues, accomplish certain objectives, or enhance the welfare of its population. The government's help in prenatal and newborn genetic testing aids in the early detection of genetic diseases or irregularities in unborn babies or infants immediately after birth. For instance, the Australian government dedicated $1.3 million yearly in June 2022 to the newborn screening initiative in New South Wales, providing free screening for severe combined immunodeficiency (SCID) and spinal muscular atrophy (SMA), as well as genetic testing for all newborns in the state. This is expected to save around 13 infants who are likely to have these genetic abnormalities out of 100,000 babies screened each year. Consequently, governmental help and strategies aimed towards prenatal testing and newborn genetic screening are driving the growth of these markets. Regarding the prenatal and newborn genetic testing market, a surge in genetic disorder rates is poised to fuel its expansion. Genetic disorders, defined as health problems arising from DNA abnormalities, can be detected early through prenatal and newborn genetic testing, often before symptoms surface. This allows prompt commencement of appropriate therapeutic responses by healthcare practitioners. The U.S. public health agency, Centers for Disease Control and Prevention, stated in May 2024 for example, that about 100,000 people in the U.S. suffer from sickle cell disease (SCD), primarily affecting the non-Hispanic Black or African American population and an estimated 3%-9% of Hispanics or Latinos. Accordingly, the escalating incidence of genetic disorders is propelling the growth of the prenatal and newborn genetic testing market.

Get Your Prenatal And Newborn Genetic Testing Market Report Here:
https://www.thebusinessresearchcompany.com/report/prenatal-and-newborn-genetic-testing-global-market-report

How will the growth rate of the prenatal and newborn genetic testing market shape industry trends by 2034?
The market size for prenatal and newborn genetic testing has experienced rapid expansion in recent years. The market is anticipated to escalate from $6.68 billion in 2024 to $7.61 billion in 2025, with a compound annual growth rate (CAGR) of 13.9%. Factors contributing to the growth during the historic period encompass improved non-invasive prenatal tests, increasing maternal age, government aid, healthcare policies, and the patient's desire for early detection.

The market size of prenatal and newborn genetic testing is forecasted to experience a swift expansion in the coming years. The market is projected to swell to $12.04 billion by 2029, with a compound annual growth rate (CAGR) of 12.1%. Factors such as broadening genetic test panels, amplified awareness about maternal health, guidelines for prenatal and newborn screening, a heightened emphasis on rare diseases along with ethical and regulatory concerns contribute to the growth anticipated in this forecast period. The forthcoming trends for this period notably include non-invasive prenatal testing (NIPT), whole genome sequencing (WGS) and whole exome sequencing, incorporation of artificial intelligence (AI), preimplantation genetic testing (PGT), and genetic testing directed straight to the consumer.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13158&type=smp

What trends are poised to drive the future success of the prenatal and newborn genetic testing market?
Top corporations in the prenatal and newborn genetic testing market have been concentrating their efforts on crafting innovative screening exams like noninvasive prenatal screening tests. They aim to enhance the availability and economical aspect of these services for customers. Noninvasive prenatal screening (NIPS), also known as noninvasive prenatal testing (NIPT), represents a highly sophisticated, secure method of genetic screening carried out during pregnancy to evaluate the likelihood of particular fetal chromosomal abnormalities. For example, Juno Diagnostics Inc., a healthcare technology firm based in the US, launched Juno Hazel in November 2022. This noninvasive prenatal screening test detects chromosomal deviations and delivers clinical data. It utilizes a sample collection kit, thus removing the need for phlebotomy and increasing accessibility. Juno Diagnostics Inc. also aims to provide educational resources and individualized genetic counseling support by connecting with physicians and genetic counselors.

Which primary segments of the prenatal and newborn genetic testing market are driving growth and industry transformations?
The prenatal and newborn genetic testing market covered in this report is segmented -

1) By Product Type: Consumables, Instruments
2) By Screening: Non-Invasive Prenatal Testing, Chronic Villus Sampling, Amniocentesis, Maternal Serum Screening, Other Screenings
3) By Disease: Down Syndrome, ket*onuria, Cystic Fibrosis, Sickle Cell Anemia
4) By End User: Hospital, Maternity And Specialty Clinics, Diagnostic Centers

Subsegments:
1) By Consumables: Reagents And Assays, Sample Collection Kits, Test Kits
2) By Instruments: Polymerase Chain Reaction (PCR) Machines, Sequencers, Microarray Analyzers

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13158

Which geographical regions are pioneering growth in the prenatal and newborn genetic testing market?
North America was the largest region in the prenatal and newborn genetic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prenatal and newborn genetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Who are the influential players reshaping the prenatal and newborn genetic testing market landscape?
Major companies operating in the prenatal and newborn genetic testing market report are F. Hoffmann-La Roche AG, Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers AG, Becton, Dickinson and Company, Quest Diagnostic Incorporated, Agilent Technologies Inc., Grifols S.A., Terumo Corporation, Illumina Inc., PerkinElmer Genomics, Quidel Corporation, Bio-Rad Laboratories Inc., Qiagen NV, Werfen S.A., DiaSorin S.p.A, Nova Biomedical, BGI Group, Natera Inc., Trinity Biotech PLC, Meridian Bioscience Inc., Sekisui Diagnostics, Chembio Diagnostics, PTS Diagnostics, Ariosa Diagnostics Inc., AccuBioTech Co. Ltd., Sequenom Inc.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/customise?id=13158&type=smp

What Is Covered In The Prenatal And Newborn Genetic Testing Global Market Report?

•Market Size Forecast: Examine the prenatal and newborn genetic testing market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the prenatal and newborn genetic testing market for a structured understanding.
•Key Players Overview: Analyze major players in the prenatal and newborn genetic testing market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the prenatal and newborn genetic testing market.
•Segment Contributions: Evaluate how different segments drive overall growth in the prenatal and newborn genetic testing market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the prenatal and newborn genetic testing market.
•Industry Challenges: Identify potential risks and obstacles affecting the prenatal and newborn genetic testing market.
•Competitive Landscape: Review strategic developments in the prenatal and newborn genetic testing market, including expansions, agreements, and new product launches.

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.